StockNews.com assumed coverage on shares of Pulmatrix (NASDAQ:PULM – Get Free Report) in a research report issued on Wednesday. The brokerage set a “hold” rating on the biotechnology company’s stock.
Pulmatrix Stock Performance
Shares of PULM opened at $2.02 on Wednesday. The firm has a market capitalization of $7.37 million, a price-to-earnings ratio of -0.52 and a beta of 0.92. Pulmatrix has a one year low of $1.55 and a one year high of $3.14. The stock’s fifty day moving average is $1.86 and its 200-day moving average is $1.88.
Pulmatrix (NASDAQ:PULM – Get Free Report) last issued its quarterly earnings results on Thursday, March 28th. The biotechnology company reported ($0.57) EPS for the quarter. The business had revenue of $2.20 million for the quarter. Pulmatrix had a negative net margin of 193.49% and a negative return on equity of 63.94%.
Pulmatrix Company Profile
Pulmatrix, Inc, a clinical stage biotechnology company, discovers and develops inhaled therapies to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company focuses on developing products based on its inhaled small particles easily respirable and emitted (iSPERSE) technology, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications.
Featured Stories
- Five stocks we like better than Pulmatrix
- 3 Grocery Stocks That Are Proving They Are Still Essential
- Charles Schwab Fortifies its Uptrend on EPS Beat
- Manufacturing Stocks Investing
- Lockheed Martin Stock Aims for a Fresh All-Time High
- What is the Shanghai Stock Exchange Composite Index?
- Beyond the Halving: The Future of Bitcoin Mining Stocks
Receive News & Ratings for Pulmatrix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pulmatrix and related companies with MarketBeat.com's FREE daily email newsletter.
